IONS insider Patrick O'Neil reports option exercises and 10b5-1 sales
Rhea-AI Filing Summary
Patrick O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS), filed a Form 4 reporting multiple transactions on September 2–3, 2025. The filing shows exercises of non-qualified stock options and contemporaneous sales executed under a Rule 10b5-1 trading plan adopted May 2, 2025. Reported option exercises include 13,050 shares at a $32.60 strike, 14,000 at $37.58, and 49,800 at $53.77. Reported sales under the 10b5-1 plan include 13,050 shares at a weighted average $54.5148, 65,475 shares at a weighted average $60.89, and 11,375 shares at a weighted average $61.42. The Form discloses the number of shares beneficially owned following each transaction line as reported in the filing.
Positive
- Sales executed under a Rule 10b5-1 trading plan, indicating transactions were pre-planned and reducing concerns about opportunistic insider trading
- Detailed disclosure of weighted-average sale prices and offer to provide per-trade details, enhancing transparency for shareholders
Negative
- Significant insider share sales (totaling tens of thousands of shares) reduced direct beneficial ownership as shown in the filing
Insights
TL;DR: Insider exercised options and sold shares via a pre-established 10b5-1 plan; disclosure aligns with governance best practices.
The filing documents option exercises and large-volume sales executed pursuant to a Rule 10b5-1 plan adopted May 2, 2025, which provides a structured, pre-planned mechanism for insider dispositions and helps mitigate appearance of opportunistic trading. The report includes weighted-average sale prices and commitments to provide transaction-level details upon request, which supports transparency. No amendment or corrective disclosure is indicated.
TL;DR: Material share sales occurred but were executed under a trading plan; net change in beneficial ownership is reported per transaction lines.
The Form 4 shows multiple option exercises (strikes $32.60, $37.58, $53.77) followed by planned sales at weighted average prices in the mid-$50s to low-$60s. These transactions increased exercised share count while reducing direct holdings through sales under the 10b5-1 plan. The filing provides sufficient price ranges and offers to supply per-trade detail on request, enabling further analysis of proceeds and timing if needed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 13,050 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right to buy) | 14,000 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right to buy) | 49,800 | $0.00 | -- |
| Exercise | Common Stock | 14,000 | $37.58 | $526K |
| Sale | Common Stock | 65,475 | $60.89 | $3.99M |
| Exercise | Common Stock | 13,050 | $32.60 | $425K |
| Sale | Common Stock | 11,375 | $61.42 | $699K |
| Exercise | Common Stock | 49,800 | $53.77 | $2.68M |
| Exercise | Non-Qualified Stock Option (right to buy) | 13,050 | $0.00 | -- |
| Exercise | Common Stock | 13,050 | $32.60 | $425K |
| Sale | Common Stock | 13,050 | $54.5148 | $711K |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to 54.59, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.3418 to $61.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.35 to $61.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5)on this Form 4.
